Analgin, 500 mg/ml 2 ml 10 pcs

Panalgin non-selectively blocks cyclooxygenase and reduces formation of prostaglandins from arachidonic acid, interferes with conduction of pain extra- and proprioceptive impulses.

Panalgin has a weak anti-inflammatory effect, resulting in little effect on water-salt metabolism (sodium and water retention) and the mucous membrane of the gastrointestinal tract.

It has antispasmodic effect on the smooth muscle of the urinary and biliary tracts. The action develops 20-40 minutes after oral administration.

Pharmacokinetics

It is well and quickly absorbed in the gastrointestinal tract, which provides rapid development of the clinical effect. When administered in therapeutic doses, it penetrates into the mother’s milk.

The maximum concentration in plasma is reached 1-1.5 hours after oral administration.

In the intestinal wall it is hydrolyzed with the formation of the active metabolite, 4-methyl-amino-antipyrine, which in turn is metabolized to 4-formyl-amino-antipyrine and other metabolites.

The level of binding of the active metabolite to proteins is 50-60%.

The excretion of metabolites passes through the kidneys. In addition, metabolites are excreted with breast milk.

Indications

Active ingredient

Composition

1 ml of the solution for injection contains:
active ingredient: sodium metamizole (analgin) 250 and 500 mg,
excipients: water for injection up to 1 ml.

How to take, the dosage

Adults and adolescents 15 years and older: as a single dose, 1-2 ml of Analgin 500 mg/mL solution or 2-4 ml of Analgin 250 mg/mL solution (intramuscularly or intravenously), the daily dose may be up to 4-8 ml of 500 mg/mL injection solution or 250 mg/mL injection solution (maximum 2 g), divided into 2-3 doses. The maximum single dose may be 1 g (2 ml of 500 mg/ml solution or 4 ml of 250 mg/ml solution).

In children and newborns: Analgin should not be administered to newborns under 3 months of age or with a body weight of less than 5 kg.

In children, Analgin is prescribed in a dose of 5-10 mg per 1 kg of body weight (0.1-0.2 ml of 500 mg/ml solution or 0.2-0.4 ml of 250 mg/ml solution).

A single dose may be administered up to 2-3 times a day.

Heating the solution to body temperature is recommended before administering.

For children aged 3-12 months the administration is by intramuscular injection only! (child’s body weight from 5 to 9 kg).

If the drug is administered too quickly, a critical drop in blood pressure and shock may occur.

Intravenous infusion should be done slowly (infusion rate of no more than 1 ml (500 mg of sodium metamizole per minute)) in the supine position, while monitoring blood pressure, pulse and respiratory rate.

Because there is concern that the drop in blood pressure of non-allergic genesis is dose-dependent, amounts of Analgin solution greater than 2 ml (1 g) should be administered with extreme caution.

Interaction

Because of the high likelihood of pharmaceutical incompatibility, it should not be mixed with other drugs in the same syringe.

The simultaneous use of analgin with other non-narcotic analgesics may result in mutually reinforcing toxic effects.

Special Instructions

In patients with bronchial asthma and pollinosis, hypersensitivity reactions may develop.

When prolonged use (more than 7 days) it is necessary to monitor the peripheral blood picture. During sodium metamizole administration agranulocytosis may develop, therefore in case of unexplained fever, chills, sore throat, difficulty in swallowing, stomatitis, erosive oral ulcers, vaginitis or proctitis the drug should be immediately discontinued.

Do not use for acute abdominal pain (until the cause is known).

To reduce the risk of gastrointestinal adverse events, the lowest effective dose should be used for the shortest possible course.

When treating patients receiving cytostatic agents, sodium metamizole should only be taken under medical supervision.

Contraindications

Side effects

The drug is usually well tolerated in therapeutic doses.

When using Analgin tablets, adverse reactions may occur in some patients:

In case of susceptibility to bronchospasm, provocation of an attack is possible.

Possible impairment of renal function.

Overdose

In case of overdose, a physician should be consulted.

The following symptoms may occur: nausea, vomiting, stomach pain, oliguria, hypothermia, decreased blood pressure, tachycardia, shortness of breath, tinnitus, drowsiness, delirium, impaired consciousness, acute agranulocytosis, hemorrhagic syndrome, acute renal and/or liver failure, seizures, respiratory muscle paralysis.

Treatment: symptomatic. There is no specific antidote for sodium metamizole. In the conditions of the hospital – forced diuresis, hemodialysis, in the development of a convulsive syndrome – intravenous administration of diazepam and fast-acting barbiturates.

Similarities